CPC C12N 9/0006 (2013.01) [A61K 31/713 (2013.01); A61K 38/443 (2013.01); A61K 38/465 (2013.01); A61K 47/61 (2017.08); A61P 1/16 (2018.01); C12N 9/22 (2013.01); C12N 9/96 (2013.01); C12N 15/11 (2013.01); C12N 15/113 (2013.01); C12N 15/1137 (2013.01); C12N 15/85 (2013.01); C12N 15/907 (2013.01); C12Q 1/32 (2013.01); C12Q 1/6827 (2013.01); C12Q 1/6876 (2013.01); C12Q 1/6883 (2013.01); C12Y 101/01051 (2013.01); C12Y 101/01062 (2013.01); G01N 33/5067 (2013.01); A61K 48/00 (2013.01); A61K 48/0066 (2013.01); C12N 2310/14 (2013.01); C12N 2310/20 (2017.05); C12N 2310/531 (2013.01); C12N 2320/30 (2013.01); C12N 2320/34 (2013.01); C12N 2800/24 (2013.01); C12N 2800/80 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/4704 (2013.01); G01N 2800/085 (2013.01)] | 26 Claims |
1. A method of treating a subject who is not a carrier of the HSD17B13 rs72613567 variant and has a chronic liver disease, the method comprising introducing into the subject an antisense molecule that hybridizes to an HSD17B13 nucleic acid molecule and decreases expression of HSD17B13 in a liver cell in the subject.
|